August 9, 2019 / 7:57 PM / 3 months ago

BRIEF-Sandoz Will Appeal District Court Of New Jersey Ruling In Biosimilar Erelzi U.S. Patent Case

Aug 9 (Reuters) - Novartis AG:

* SANDOZ WILL APPEAL DISTRICT COURT OF NEW JERSEY RULING IN BIOSIMILAR ERELZI® (ETANERCEPT-SZZS) US PATENT CASE

* SANDOZ TO APPEAL COURT RULING TO UNITED STATES COURT OF APPEALS FOR FEDERAL CIRCUIT

* FRIDAY RULING PREVENTS LAUNCH OF IMPORTANT, AFFORDABLE TREATMENT OPTION FOR US PATIENTS AFFECTED BY CHRONIC AUTOIMMUNE AND INFLAMMATORY DISEASES

* SANDOZ REMAINS COMMITTED TO PROVIDING ERELZ AS SOON AS POSSIBLE

* US DISTRICT COURT OF NEW JERSEY RULED AGAINST SANDOZ IN PATENT LITIGATION CONCERNING SANDOZ BIOSIMILAR, ERELZI FOR REFERENCE MEDICINE ENBREL

* SANDOZ WILL APPEAL RULING TO US COURT OF APPEALS FOR FEDERAL CIRCUIT, AND PARTIES HAVE AGREED TO AN EXPEDITED APPEAL. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below